Parallax Volatility Advisers
ABUS icon

Parallax Volatility Advisers’s Arbutus Biopharma ABUS Stock Holding History

Parallax Volatility Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30,000
Closed -$115K – 2686
2018
Q4 		$115K Sell
30,000
-20,000
-40% -$98.5K ﹤0.01% 1898
2018
Q3 		$472K Sell
50,000
-50,000
-50% -$496K ﹤0.01% 1446
2018
Q2 		$730K Buy
+100,000
New +$595K ﹤0.01% 1174

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallax Volatility Advisers's ABUS Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 200,528 shares — an estimated $383K sold.

Parallax Volatility Advisers first reported a position in ABUS in Q4 2018 and held it in 4 quarters. The position peaked at $597K in Q1 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 200,528 Arbutus Biopharma shares in Q4 2022, an estimated $383K.
  • Parallax Volatility Advisers first reported a position in Arbutus Biopharma in Q4 2018 and held it in 4 quarters.
  • Parallax Volatility Advisers's Arbutus Biopharma position peaked at $597K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.